X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (1555) 1555
Paper (822) 822
Publication (647) 647
Report (195) 195
Book / eBook (10) 10
Data Set (6) 6
Book Review (3) 3
Book Chapter (2) 2
Conference Proceeding (1) 1
Dissertation (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
experiment (895) 895
physics (849) 849
high energy physics - experiment (811) 811
particle physics (802) 802
cern lhc coll (748) 748
experimental results (739) 739
physics - high energy physics - experiment (737) 737
high energy physics (616) 616
p p: scattering (577) 577
cms (543) 543
p p: colliding beams (517) 517
physics of elementary particles and fields (443) 443
phenomenology (390) 390
13000 gev-cms (379) 379
hep (283) 283
particle physics - experiment (270) 270
scattering [p p] (267) 267
nuclear experiment (258) 258
physics, particles & fields (237) 237
hadron-hadron scattering (235) 235
colliding beams [p p] (226) 226
8000 gev-cms (221) 221
background (207) 207
[phys.hexp]physics [physics]/high energy physics - experiment [hep-ex] (176) 176
ex (163) 163
physical sciences (139) 139
elementary particles, quantum field theory (136) 136
quantum field theories, string theory (136) 136
supersymmetry (128) 128
index medicus (127) 127
natural sciences (123) 123
naturvetenskap (123) 123
astrophysics (119) 119
astronomy & astrophysics (118) 118
fysik (116) 116
[ phys.hexp ] physics [physics]/high energy physics - experiment [hep-ex] (115) 115
transverse momentum: missing-energy (115) 115
channel cross section: upper limit (109) 109
cern lab (108) 108
humans (107) 107
mass dependence (103) 103
final state:jet lepton (97) 97
high energy astrophysical phenomena (95) 95
classical and quantum gravitation, relativity theory (92) 92
quantum physics (92) 92
collisions (91) 91
transverse momentum dependence (87) 87
data analysis method (83) 83
kinematics (80) 80
top: pair production (79) 79
bottom: particle identification (77) 77
large hadron collider (77) 77
jet: bottom (76) 76
rapidity dependence (76) 76
muon: pair production (73) 73
z0: leptonic decay (73) 73
female (71) 71
male (70) 70
instrumentation and detectors (69) 69
nuclear physics (69) 69
transverse momentum (69) 69
channel cross section: branching ratio: upper limit (68) 68
higgs particle: hadroproduction (68) 68
decay (67) 67
114 physical sciences (64) 64
physics, nuclear (63) 63
channel cross section: measured (62) 62
final state:jet dilepton (62) 62
luminosity (62) 62
quantum chromodynamics: perturbation theory (62) 62
mass spectrum: (61) 61
physics, multidisciplinary (61) 61
nuclear and high energy physics (59) 59
analysis (57) 57
jet: transverse momentum (57) 57
electroweak interaction (55) 55
lead (55) 55
differential cross section: measured (53) 53
sensitivity (53) 53
detectors (52) 52
beyond standard model (51) 51
bottom: pair production (51) 51
physics and astronomy (50) 50
new physics: search for (49) 49
astronomy, astrophysics and cosmology (48) 48
hep-ex (48) 48
mass: lower limit (48) 48
squark: pair production (48) 48
upper limit [channel cross section] (47) 47
w: leptonic decay (47) 47
middle aged (46) 46
searching (46) 46
final state:jet (45) 45
jet lepton (45) 45
jet: multiplicity (45) 45
measurement science and instrumentation (44) 44
nuclear energy (44) 44
nuclear physics, heavy ions, hadrons (44) 44
gravitation (43) 43
life sciences (43) 43
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet, The, ISSN 0140-6736, 2011, Volume 378, Issue 9785, pp. 41 - 48
Journal Article
by Rosell, Rafael, Dr and Carcereny, Enric, MD and Gervais, Radj, MD and Vergnenegre, Alain, Prof and Massuti, Bartomeu, MD and Felip, Enriqueta, MD and Palmero, Ramon, MD and Garcia-Gomez, Ramon, MD and Pallares, Cinta, MD and Sanchez, Jose Miguel, MD and Porta, Rut, MD and Cobo, Manuel, MD and Garrido, Pilar, MD and Longo, Flavia, MD and Moran, Teresa, MD and Insa, Amelia, MD and De Marinis, Filippo, MD and Corre, Romain, MD and Bover, Isabel, MD and Illiano, Alfonso, MD and Dansin, Eric, MD and de Castro, Javier, MD and Milella, Michele, MD and Reguart, Noemi, MD and Altavilla, Giuseppe, MD and Jimenez, Ulpiano, MD and Provencio, Mariano, MD and Moreno, Miguel Angel, MD and Terrasa, Josefa, MD and Muñoz-Langa, Jose, MD and Valdivia, Javier, MD and Isla, Dolores, MD and Domine, Manuel, MD and Molinier, Olivier, MD and Mazieres, Julien, Prof and Baize, Nathalie, MD and Garcia-Campelo, Rosario, MD and Robinet, Gilles, MD and Rodriguez-Abreu, Delvys, MD and Lopez-Vivanco, Guillermo, MD and Gebbia, Vittorio, MD and Ferrera-Delgado, Lioba, MD and Bombaron, Pierre, MD and Bernabe, Reyes, MD and Bearz, Alessandra, MD and Artal, Angel, MD and Cortesi, Enrico, MD and Rolfo, Christian, MD and Sanchez-Ronco, Maria, PhD and Drozdowskyj, Ana, PhD and Queralt, Cristina, PhD and de Aguirre, Itziar, PhD and Ramirez, Jose Luis, PhD and Sanchez, Jose Javier, Prof and Molina, Miguel Angel, PhD and Taron, Miquel, PhD and Paz-Ares, Luis, MD and Assoc Italiana Oncologia Toracica and Grp Francais Pneumocancerologie and Spanish Lung Cancer Group in collaboration with Groupe Français de Pneumo-Cancérologie and Associazione Italiana Oncologia Toracica
Lancet Oncology, The, ISSN 1470-2045, 2012, Volume 13, Issue 3, pp. 239 - 246
Summary Background Erlotinib has been shown to improve progression-free survival compared with chemotherapy when given as first-line treatment for Asian... 
Hematology, Oncology and Palliative Medicine | IPASS | GEFITINIB | THERAPY | ONCOLOGY | SENSITIVITY | CARBOPLATIN/PACLITAXEL | TUMORS | Erlotinib Hydrochloride | Lung Neoplasms - drug therapy | Receptor, Epidermal Growth Factor - genetics | Prospective Studies | Exons | Lung Neoplasms - mortality | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Lung Neoplasms - pathology | Male | Protein Kinase Inhibitors - adverse effects | Molecular Targeted Therapy | Cisplatin - administration & dosage | Patient Selection | Time Factors | Female | Quinazolines - administration & dosage | Precision Medicine | Carcinoma, Non-Small-Cell Lung - pathology | Lung Neoplasms - genetics | Lung Neoplasms - enzymology | Drug Administration Schedule | Administration, Oral | Carcinoma, Non-Small-Cell Lung - genetics | Deoxycytidine - administration & dosage | Europe | Kaplan-Meier Estimate | Proportional Hazards Models | Carboplatin - administration & dosage | Treatment Outcome | Chi-Square Distribution | Carcinoma, Non-Small-Cell Lung - mortality | Disease-Free Survival | Protein Kinase Inhibitors - administration & dosage | Taxoids - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Quinazolines - therapeutic use | Quinazolines - adverse effects | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Carcinoma, Non-Small-Cell Lung - enzymology | Mutation | Deoxycytidine - analogs & derivatives | Antimitotic agents | Care and treatment | Chemotherapy | Erlotinib | Lung cancer | Product development | Agriculture | Lung cancer, Non-small cell | Antineoplastic agents | Standards | Cancer
Journal Article
JACC (Journal of the American College of Cardiology), ISSN 0735-1097, 2017, Volume 69, Issue 12, pp. 1536 - 1544
Abstract Background The long-term effect of thrombolytic treatment of pulmonary embolism (PE) is unknown. Objectives This study investigated the long-term... 
Cardiovascular | Internal Medicine | chronic thromboembolic pulmonary hypertension | thrombolysis | long-term survival | pulmonary embolism | prognosis | DIAGNOSIS | CARDIAC & CARDIOVASCULAR SYSTEMS | MANAGEMENT | GUIDELINES | CARDIOLOGY ESC | EUROPEAN-SOCIETY | TIME TRENDS | TRIAL | TASK-FORCE | HYPERTENSION | Pulmonary Embolism - prevention & control | Echocardiography | Double-Blind Method | Humans | Middle Aged | Male | Treatment Outcome | Tissue Plasminogen Activator - therapeutic use | Pulmonary Embolism - mortality | Fibrinolytic Agents - therapeutic use | Thrombolytic Therapy | Aged, 80 and over | Female | Aged | Tenecteplase | Pulmonary Embolism - diagnostic imaging | Pulmonary embolism | Stroke (Disease) | Medicine, Experimental | Medical research | Cardiology | Cardiovascular agents | Heart | Therapy | Chest | Incidence | Design | Computed tomography | Motivation | Tomography | Diagnosis | Thromboembolism | Anticoagulants | Pulmonary arteries | Mortality | Statistical tests | Patients | Fibrinolysis | Survival | Computation | Diagnostic software | Death | Health risk assessment | Risk management | Angiography | Arches | Embolisms | Medical services | Clinical trials | Population studies | Hemorrhage | Bleeding | Guidelines | Reperfusion | Risk assessment | Calcium-binding protein | Trends | Heart diseases | Injuries | Hypertension | Collapse | Stroke | Statistical analysis | Receiving | Steering | Complications | Risk reduction | Statistics | Pulmonary hypertension | Embolism | Computer programs | Contact | Thromboplastin | Medical prognosis | Fatalities | Ventricle | Heparin | Life Sciences | Human health and pathology | Cardiology and cardiovascular system
Journal Article
JACC (Journal of the American College of Cardiology), ISSN 0735-1097, 2012, Volume 59, Issue 24, pp. 2175 - 2181
Journal Article
Lancet Neurology, The, ISSN 1474-4422, 2016, Volume 15, Issue 6, pp. 574 - 584
Journal Article
Journal Article
Journal Article
Journal of Cardiology, ISSN 0914-5087, 2015, Volume 67, Issue 3, pp. 248 - 253
Journal Article